Table 3.
Subgroup analysis
| Subgroup | No. of Participants | ESKD Cases | CVD Subtypes, HR (95% CI) | |||
|---|---|---|---|---|---|---|
| Heart Failure | Atrial Fibrillation | Coronary Heart Disease | Stroke | |||
| Age, yr | ||||||
| <65 | 5660 | 96 | 11.12 (7.06 to 17.54) | 2.94 (1.65 to 5.23) | 2.31 (1.17 to 4.57) | 1.22 (0.53 to 2.84) |
| ≥65 | 3387 | 114 | 12.39 (8.16 to 18.82) | 2.53 (1.61 to 3.98) | 4.67 (2.96 to 7.37) | 1.45 (0.71 to 2.94) |
| P for interaction | 0.20 | 0.21 | 0.06 | 0.17 | ||
| Sex | ||||||
| Male | 3752 | 98 | 12.03 (7.64 to 18.94) | 1.82 (1.07 to 3.09) | 3.80 (2.26 to 6.40) | 1.48 (0.71 to 3.08) |
| Female | 5295 | 112 | 13.37 (8.79 to 20.33) | 4.74 (2.89 to 7.79) | 4.08 (2.35 to 7.08) | 1.30 (0.59 to 2.90) |
| P for interaction | 0.41 | 0.02 | 0.57 | 0.85 | ||
| Race | ||||||
| White | 7105 | 128 | 10.34 (6.92 to 15.46) | 3.08 (2.06 to 4.62) | 3.69 (2.36 to 5.78) | 1.57 (0.80 to 3.08) |
| Black | 1942 | 82 | 14.71 (9.08 to 23.84) | 1.62 (0.68 to 3.89) | 3.42 (1.72 to 6.80) | 1.27 (0.53 to 3.07) |
| P for interaction | 0.90 | 0.05 | 0.71 | 0.50 | ||
| Diabetes | ||||||
| No | 7752 | 119 | 11.45 (7.48 to 17.51) | 2.11 (1.32 to 3.37) | 3.55 (2.15 to 5.86) | 0.97 (0.42 to 2.26) |
| Yes | 1295 | 91 | 11.74 (7.38 to 18.68) | 3.72 (2.15 to 6.44) | 3.89 (2.19 to 6.92) | 1.87 (0.93 to 3.79) |
| P for interaction | 0.63 | 0.43 | 0.85 | 0.36 | ||
| CKD | ||||||
| No | 8067 | 111 | 9.11 (5.94 to 13.96) | 2.99 (1.87 to 4.78) | 2.68 (1.56 to 4.59) | 1.14 (0.46 to 2.82) |
| Yes | 980 | 99 | 14.67 (9.28 to 23.19) | 2.20 (1.28 to 3.76) | 5.16 (3.05 to 8.71) | 1.93 (0.97 to 3.81) |
| P for interaction | 0.98 | 0.26 | 0.35 | 0.84 | ||
The model was adjusted for age, sex, race, body mass index, ever smoking, ever drink, years of education, systolic BP, antihypertensive drugs, diabetes, eGFR, ACR, CRP, total cholesterol, HDL-C, and history of COPD and cancer. The covariates were updated when available.